Application of the AMLprofiler diagnostic microarray in the South African setting

dc.contributor.authorKappala, S.S.
dc.contributor.authorAlessandrini, Marco
dc.contributor.authorMatlhako, T.
dc.contributor.authorBeltchev, E.
dc.contributor.authorPool, Roger
dc.contributor.authorPepper, Michael Sean
dc.contributor.emailmichael.pepper@up.ac.zaen_ZA
dc.date.accessioned2017-11-30T06:14:16Z
dc.date.available2017-11-30T06:14:16Z
dc.date.issued2017-11-07
dc.description.abstractAcute myeloid leukemia (AML) is characterized by proliferation of the myeloid lineage and accumulation of immature hematopoietic cells in the bone marrow and is typified by marked heterogeneity both in response to treatment and survival. AMLprofiler is a qualitative in vitro diagnostic microarray incorporating seven molecular biomarkers used to diagnose and predict posttherapy survival rates. In this study, we compared AMLprofiler to routine AML diagnostic methodologies employed in South Africa, focusing on consistency of the results, cost, and time to result. RNA was isolated from bone marrow and peripheral blood samples from patients with de novo AML and was processed using Affymetrix Gene Profiling Reagent kits. The results from AMLprofiler and standard methodologies were highly comparable. In addition, many samples were determined to be positive for biomarkers not routinely investigated in South Africa, namely, CEBPA double mutants, NPM1 variants, and altered expression levels of BAALC and EVI1. 38% of samples presented with no positive biomarker; AMLprofiler nonetheless enabled 26% of AML patients to be classified into either favorable or poor prognostic categories. This study highlights the comprehensive nature of the microarray. Decreased time to result and refinement of risk stratification are notable benefits.en_ZA
dc.description.departmentHaematologyen_ZA
dc.description.departmentImmunologyen_ZA
dc.description.librarianam2017en_ZA
dc.description.sponsorshipThe University of Pretoria (Institute for Cellular and Molecular Medicine and Vice Chancellor’s post-doctoral fellowship), the National Health Laboratory Services Research Trust, the South African Medical Research Council (Category 1 University Flagship and Extramural Stem Cell Unit grants), and the National Research Foundation of South Africa.en_ZA
dc.description.urihttps://www.hindawi.com/journals/scien_ZA
dc.identifier.citationKappala, S.S. ... et al. 2017, 'Application of the AMLprofiler diagnostic microarray in the South African setting', Stem Cells International, vol. 2017, art. no. 2560191, pp. 1-8.en_ZA
dc.identifier.issn1687-966X (print)
dc.identifier.issn1687-9678 (online)
dc.identifier.other10.1155/2017/2560191
dc.identifier.urihttp://hdl.handle.net/2263/63384
dc.language.isoenen_ZA
dc.publisherHindawi Publishing Corporationen_ZA
dc.rights© 2017 S. S. Kappala et al. This is an open access article distributed under the Creative Commons Attribution License.en_ZA
dc.subjectMyeloid lineageen_ZA
dc.subjectTreatmenten_ZA
dc.subjectDiagnoseen_ZA
dc.subjectAcute myeloid leukemia (AML)en_ZA
dc.subjectAdult patientsen_ZA
dc.subjectNucleophosmin mutationsen_ZA
dc.subjectCytogeneticsen_ZA
dc.subjectBinding protein-α (C/EBPα)en_ZA
dc.subject.otherHealth sciences articles SDG-03
dc.subject.otherSDG-03: Good health and well-being
dc.subject.otherHealth sciences articles SDG-09
dc.subject.otherSDG-09: Industry, innovation and infrastructure
dc.subject.otherHealth sciences articles SDG-17
dc.subject.otherSDG-17: Partnerships for the goals
dc.titleApplication of the AMLprofiler diagnostic microarray in the South African settingen_ZA
dc.typeArticleen_ZA

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Kappala_Application_2017.pdf
Size:
1.17 MB
Format:
Adobe Portable Document Format
Description:
Article

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.75 KB
Format:
Item-specific license agreed upon to submission
Description: